Abstract

The present invention discloses a continuous process for the direct capture of CO2 from the atmospheric air. The present invention specifically discloses the use of phase change amine (solid-liquid) absorbents with suitable solvents, yielding efficient CO2 capture from air. This cyclic approach establishes a continuous method for capturing CO2 directly from air, characterized by significantly reduced energy demand. More particularly, the present invention provides an energy efficient method for capturing CO2 directly from air, using phase change amines, with low regeneration energy.

IPC Classes  ?

• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/62 - Carbon oxides
• B01D 53/74 - General processes for purification of waste gasesApparatus or devices specially adapted therefor
• B01D 53/77 - Liquid phase processes
• B01D 53/92 - Chemical or biological purification of waste gases of engine exhaust gases
• B01D 53/96 - Regeneration, reactivation or recycling of reactants

IPC Classes  ?

• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 27/26 - Cyanides
• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds

IPC Classes  ?

• A61K 8/06 - Emulsions
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

IPC Classes  ?

• C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 36/185 - Magnoliopsida (dicotyledons)
• C07D 295/16 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms

Abstract

The present invention relates to the process of enrichment of Phytocannabinoids namely CBD and 9-THC from the dried aerial part (leaves and inflorescence) of Cannabis sativa. The present invention also relates to the preparation of formulation having enriched CBD and THC by combining with appropriate acceptable excipients such as nutriose, dextrin and maltodextrin. The present invention also discloses the use of the phytocannabanoids enriched blend for the management of pain including cancer pain & general pain.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• B01D 15/08 - Selective adsorption, e.g. chromatography
• G01N 30/02 - Column chromatography

Abstract

The present invention relates to a cell-penetrating peptide and its derivatives to inhibit -synuclein fibrillation. The present invention specifically relates to a peptide-based inhibitor of Parkinson's Disease. The present invention discloses the identification of the peptides permeable to blood brain barrier for inhibition. -synuclein fibril formation is observed in the presence of peptides as indicated by SEQ. ID-7, SEQ. ID-8 wherein the SEQ. ID-7, SEQ. ID-8 are truncated versions of SEQ. ID-4 having the homology of 83% and 75% respectively. It provides a peptide having an amino acid sequence of Formula 1. The present invention also provides a pharmaceutical composition comprising a peptide of Formula 1 along with the pharmaceutically acceptable excipient(s) having inhibitory activity against ß-sheet polymerisation of amyloidogenic proteins. The analysis showed that peptides corresponding to SEQ. ID-7, SEQ. ID-8 are better inhibitors than SEQ. ID-4 against -synuclein fibrillation.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof

Abstract

Trypsin/trypsin-like proteases have been reported to be facilitating SARS-CoV-2 entry into host cells. Spike has protease cleavage sites between the S1 and S2 domains. Cleavage property of proteases can be used to design drug screening assays meant for screening antiviral candidates against spike cleavage. In the claimed invention we have developed a proof-of-concept assay system for screening drugs against proteases which cleave spike between S1 and S2. We designed a fusion substrate protein containing a reporter protein, the protease cleavage site between S1 and S2 and a cellulose binding domain. The substrate protein can be immobilized on cellulose due to the presence of cellulose binding domain (CBD). When proteases cleave the substrate, CBD remains bound to cellulose and the reporter protein is dislodged. The released reporter can be used as read out of protease activity.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus

Abstract

The present invention provides a method for the preparation of building blocks of 2,7-dihydroxy-9-fluorenone towards the synthesis of tilorone dihydrochloride salt and other salts (bromide, iodide, fluoride, citrate, oxalate, maleate, phosphate, tartrate, triflate, trifluoroacetate, tetrafluoroborate) of Tilorone. An efficient, safe, cost effective method for the preparation of 2,7-bis-[2-(diethylamino)ethoxy]-fluorenone-9 and its various salts is developed. Method involves oxygenation of fluorene, nitration of fluorenone followed by reduction and diazotization towards the formation of 2,7-dihydroxy-9-fluorenone which is the key intermediate for the formation of 2,7-bis-[2-(diethylamino)ethoxy]- 9- fluorenone- dihydrochloride (Tilorone dihydrochloride) and other tilorone salts. The current synthesis method of the invention has relatively simple operation, mild reaction conditions, high yield and simple process with, yield 80-97%. Subsequent product purification of this method uses filtration and crystallization methods, avoiding the existing methods of column chromatography.

IPC Classes  ?

• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61P 31/12 - Antivirals
• C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
• C07C 217/22 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms

Abstract

The present invention conveys a fractionation method to isolate different bioactive Phytocannabinoids by solid phase extraction using HP-20 resins and one step method to synthesize C- and O-?-D-glycoside derivatives of Cannabinoid by using a ?-D-glucose donor (O-Glycosyl trichloroacetimidate donor) to obtain glycosidic derivatives. The novel C-glycosides of Cannabinoids displayed significant anti-proliferative properties against wide range of human cancer cell lines as compared to their respective parent molecules. Furthermore, the C- and O glycosides of Cannabinoids also showed anti-invasive and anti-migratory activities against metastatic cancer cells of breast and pancreatic origin. When applied in combination with DNA damaging agent (5-Fluorouracil) to colorectal cancer cells, the C- and O-glycosides of Cannabinoids potentiate DNA damaging property and thus augment apoptosis resulting in an increment in the efficacy of DNA damaging drugs.

IPC Classes  ?

• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07H 1/08 - SeparationPurification from natural products
• C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms

Abstract

Engineered FnCas9 variants are provided that have an enhanced kinetic activity and a broader PAM recognition. The protein engineering methodology introduced specific mutations that stabilized interaction between Cas9 enzyme and target DNA. The enhanced kinetic activity increases NHEJ-mediated editing, owing to more efficient DSB generation potential than WT FnCas9, and the broadened PAM specificity increases the target range of FnCas9 variants. Thus, the scope and accessibility of CRISPR-Cas9 system targets are widened, along with generating robust and highly specific engineered FnCas9 variants.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/52 - Proteinases derived from bacteria
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

There is provided a complex of a 6,7-dihydroxy coumarin phosphonium amphiphile together with a negatively charged agent. The complex self-assembles into a nanoparticle or non-viral vector for facilitating delivery of the negatively charged agent. The negatively charged agent may be a therapeutic agent or a diagnostic agent. Thus, the present invention provides a method of delivery of such negatively charged agents to a target cell, and in particular facilitates delivery of a therapeutic or diagnostic agent across the plasma membrane, as well as a method of treatment or diagnosis via delivery of the therapeutic or diagnostic agent. The 6,7-dihydroxy coumarin phosphonium amphiphile can be Mito-Esc and the negatively charged agent can be a nucleic acid such as siRNA. Additionally, the 6,7-dihydroxy coumarin phosphonium amphiphile is believed to be effective in the treatment of cancer.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07F 9/54 - Quaternary phosphonium compounds

Abstract

The present invention relates to the method for preparation of a cathode active material composition for a lithium-ion battery, which is cost-effective and time-effective. Another embodiment of the present invention is the cathode active material composition, Lix(Ni1-y-zMnyCoz)1-aM'aO2 (1.0=x=1.1, 0.25=y=0.3, 0.15=z=0.2, 0

IPC Classes  ?

• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

The present invention relates to novel SMAC mimetic peptidomimetics useful for the treatment of proliferative diseases including cancer in mammals. The novel SMAC mimetics are prepared by incorporating (2S,5R)-5-(5-methylfuran-2-yl)pyrrolidine-2-carboxylic acid, a novel unnatural amino acid that imparts exclusively trans amide bond geometry favourable for target protein binding. Here, the novel SMAC mimetic molecule(s) not only show its efficacy in varied cancer types but also demonstrate in vitro and in vivo efficacy against therapy resistant cancer as a single agent. The novel SMAC mimetics disclosed in the present invention binds to BIR-2 and BIR-3 domains of the XIAP and exhibit high anti-proliferative activity against variety of mammalian cancer cell lines that include but not limited to chemotherapy and TRAIL resistant cell lines.

IPC Classes  ?

• A61K 38/07 - Tetrapeptides
• C07K 1/06 - General processes for the preparation of peptides using protecting groups or activating agents
• C07K 1/10 - General processes for the preparation of peptides using coupling agents
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in particular for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds having Structure I arecapable of increasing the level of adipose triglyceride lipase (ATGL). Also provided is the process of preparing compounds having Structure I.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07D 239/88 - Oxygen atoms
• C07D 239/90 - Oxygen atoms with acyclic radicals attached in position 2 or 3
• C07D 239/91 - Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
• C07D 239/92 - Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a composition for fuel cell membranes and a process for the preparation thereof. In particular, the present invention relates to thermo-mechanically and chemically stable polymer electrolyte membranes which have been prepared without compromising proton conductivity by using multifunctional polydopamine and mechanically robust nanocellulose.

IPC Classes  ?

• C08J 5/22 - Films, membranes or diaphragms
• H01M 8/00 - Fuel cellsManufacture thereof

Abstract

The present invention discloses a kit and a novel method of extraction of a progesterone metabolite from feces/dung sample. The present invention also discloses a paper-based microfluidic device for detection of the progesterone metabolite for early determination of pregnancy in cattle and buffaloes. The invention further discloses antibodies developed against said metabolite, method of extraction, methods for fabricating the paper-based microfluidic devices and methods for inexpensive, rapid and non-invasive determination of pregnancy in early stages in cattle and buffaloes.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

The present invention provides an energy storage device having high discharge capacity and high cycling ability. More particularly, the present invention provides Zn/V2O5 battery having cation selective ionomer membrane and free-standing electrode.

IPC Classes  ?

• B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present invention is related to the novel solid dispersion formulations of an anticancer compound of formula A and a process for preparing the same wherein the anticancer compound is formulated with hydrophilic polymer. The said formulation showed enhanced dissolution of the anticancer compound and improved in-vivo anticancer activity. The said formulations are useful for the treatment of various types of cancer.

IPC Classes  ?

• A61K 9/10 - DispersionsEmulsions
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention provides the sulfonyl hydroxamic acid compounds of general formulae (I) useful as HDAC inhibitors and process for preparation of these indole based sulfonyl hydroxamic acid derivatives. wherein ring A and B is aryl or heteroaryl or cycloalkyl or fused aryl or fused alkyl group; R1, R2, R3, R4, R5, R6 is hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, aldehyde.

IPC Classes  ?

• C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Abstract

The present invention provides novel purine based compounds of formula 1, method of preparation of purine based compounds and its composition useful for inhibiting signalling through Toll-like receptors. These compounds are useful in inhibiting immune stimulation involving toll -like receptor 9 (TLR9). These can be used in treatment of autoimmune disease and inflammation where aberrant activation of TLR9 plays role.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61P 37/02 - Immunomodulators
• C07D 473/16 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Abstract

The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/ or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24hrs. The said formulations are useful for the treatment of inflammatory diseases.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 36/185 - Magnoliopsida (dicotyledons)

Abstract

The present invention relates to a novel cloning, expression and refolding process for preparing antibody fragments. More particularly, the present invention relates to a cloning, expression and refolding platform for preparing recombinant humanized (rHu) Ranibizumab.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
• C07K 1/14 - ExtractionSeparationPurification
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present invention relates to small molecule4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defence for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3Ka inhibition and their medicinal use as anticancer agents.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• C07D 495/04 - Ortho-condensed systems

Abstract

A system for spraying liquid pesticides with enhanced performance to crops and orchards, combines an air-assisted nozzle and electrostatic induction charging, low voltage dc power supply raised to several kilovolts which is applied to a ring electrode embedded at a selected distance in the nozzle, spray nozzle made of insulating material to avoid the shock and hazardous, an external air assistance system which supplies compressed air to assist the finely divided liquid spray, movable support system for air supplies whose variation of spray coverage is from parallel to the spray center line (0°) to maximum target spray coverage, flexible spring system to compress or elongate the air supply to change the spray coverage, manually controlled trigger system to compress or elongate the springs, to transport electrostatically charged droplets to intended target with variable spray canopy coverage, applicable in high wind and transient agro-climatic conditions.

IPC Classes  ?

• B05B 5/03 - Discharge apparatus, e.g. electrostatic spray guns characterised by the use of gas
• B05B 12/00 - Arrangements for controlling deliveryArrangements for controlling the spray area

Abstract

The present invention relates to the compounds of formula I wherein R is as herein described. The present invention particularly relates to synthesis and antiproliferative activity of 10-substituted colchicinoids. Compounds of the invention can be used for prevention or in the treatment of cancer disease.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61P 35/00 - Antineoplastic agents
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Abstract

The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R" are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-a (PI3K-a) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents
• C07D 239/94 - Nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to an improved process for the preparation of 2,5-dimethylfuran and furfuryl alcohol over ruthenium supported catalysts. Further, the present invention disclosed a process for the selective hydrogenolysis of biomass derived 5-hydroxymethylfurfural (HMF) into 2,5-dimethylfuran (DMF) using Ru nanoparticles supported on NaY zeolite as a catalyst.

IPC Classes  ?

• C07D 307/36 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• C07D 307/44 - Furfuryl alcohol
• C07D 307/48 - Furfural

Abstract

The present invention discloses a process for the preparation of poly-benzimidazole (PBI) based membrane electrode assembly (MEA) with improved fuel cell performance and stability. It discloses a simple strategy to overcome the leaching of phosphoric acid (PA) from the membrane during fuel cell operation by an in-situ Current- Voltage (I-V) assisted doping of membrane with PA. The invention provides an improved method for the preparation of membrane electrode assembly (MEA) wherein said MEA possess high stability and improved fuel cell performance achieved by overcoming the leaching of phosphoric acid during cell operation.

IPC Classes  ?

• H01M 4/92 - Metals of platinum group
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte

Abstract

The present invention provides 3-(4-ethynylphenyl) pyridopyrimidinone compounds of formula A as potential anticancer agents. 3-(4-ethynylphenyl) pyridopyrimidinone compounds have shown promising anticancer activity in various cell lines sixty human cancer cell lines.[Formula A] Wherein [Formula B] R1= H, OH, OCH3 R2= H, OH, CH3, OCH3, N02 R3= H, OH, OCH3, F, CI R4= H, OH, CH3, OCH3 R5= H, OH, CH3, OCH3 R6= H, OCH3 R2+R3= -0CH2O-

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention discloses a process for depolymerization of lignin to yield substituted phenolic monomers using Brönsted ionic liquid as catalyst under mild reaction conditions to obtain an overall yield of monomers up to 97%.

IPC Classes  ?

• C07G 1/00 - Low-molecular-weight derivatives of lignin
• C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters
• C08L 97/00 - Compositions of lignin-containing materials

Abstract

Disclosed herein are novel antifungal compounds of Formula 1, containing 1 -substituted, 4-(substituted phenoxymethyl)-l,2,3-triazole moieties coupled to a core having triazole ring, (un)substituted phenyl ring and tertiary alcoholic functionality, and pharmaceutically acceptable salts thereof; methods for preparing these compounds; and pharmaceutical preparations containing these novel compounds for prevention and treatment of fungal infections.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Disclosed herein are novel antifungal compounds of Formula 1, containing fluconazole pharmacophore moieties coupled with other moieties including aryl enones and chalcones and pharmaceutically acceptable salts thereof, methods for preparing these compounds and pharmaceutical preparations containing these novel compounds for prevention and treatment of fungal infections.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 31/10 - Antimycotics
• C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

PBI-based MEAs for high temperature Polymer Electrolyte Membrane Fuel Cell (PEMFC) were prepared by direct hot pressing of catalyst layer on Teflon sheets on to both sides of phosphoric acid doped PBI membrane (decal transfer). These MEAs show two times higher performance compared to the MEAs prepared by normal brush coating method on GDL at an operating temperature of 160°C.

IPC Classes  ?

• H01M 8/0297 - Arrangements for joining electrodes, reservoir layers, heat exchange units or bipolar separators to each other
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]

Abstract

The present invention discloses novel enantiomeric antifungal compounds of Formula (1a) and Formula (1b) containing thieno-[2,3-d]Jpyrimidin-4(3H)-one moiety and pharmaceutically acceptable salts thereof, method of preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these compounds.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 495/04 - Ortho-condensed systems

Abstract

The present invention provides a method of tandem cropping for increased production of up to 40% in wheat and mustard crops using varieties with phenological plasticity and temperature tolerance traits. The cereal bread wheat and oil seed mustard are traditional winter season (Rabi) crops in north India/ Indo-Gangetic plains. This area experiences receding levels of warm weather and long days in September, October and November, progressive increase and then decrease of cold conditions and short days between November and March and onset of warm weather turning into summer and relatively longer days in March and April. Conventionally a seasonal crop of wheat or mustard or wheat followed by mustard or vice versa could be taken in the winter Rabi season of Indo-Gangetic plains to increase the production of these commodities. The concept has not occurred to persons skilled in the art of wheat cultivation and breeding and as far as is known there is no report of tandem cultivation of wheat under natural seasonal changes of agro-climates in areas where wheat cultivation is practised. For tandem cropping, wheat and mustard cultivars must posses properties of flowering under long day or short day conditions, tolerating temperature gradients and reaching maturity earlier than normal.

IPC Classes  ?

• A01G 7/00 - Botany in general